Pathogenic role of IFNγ from activated CD4+ T cells in lupus model mice induced by topical treatment with toll-like receptor agonist imiquimod
Clinical and Experimental Immunology · 2026
DOI: 10.1093/cei/uxaf079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2026. Verfasst von Reona Tanimura und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba City, Ibaraki 305-8575, Japan. Hauptthemen laut MEDLINE: Imiquimod, Lupus Erythematosus, Systemic, Interferon-gamma, CD4-Positive T-Lymphocytes. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: GSK Japan Research, JST, Science Technology Innovation.
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ involvement. It is known that cytokines produced from activated CD4+ T cells play a pivotal role in the development of SLE; however, the details of pathological processes remain unclear. The purpose of this study is to elucidate the role of activated CD4+ T cells on the pathogenesis of lupus using SLE murine models induced by toll like receptor 7 agonist imiquimod (IMQ). Lupus was induced in wild-type (WT) and interferon γ (IFNγ)-deficient (IFNγ−/−) mice by topical IMQ treatment. Splenic T and B cell subsets were analyzed by flow cytometry. CD4+ T cells and B cells were isolated for co-culture to assess B cell differentiation and IgG production. Comprehensive lupus-like phenotypes were evaluated. Single-cell RNA sequencing (scRNA-seq) was performed to characterize IFNγ-associated cellular and molecular pathways. IMQ treatment increased IFNγ-producing CD4+ T cells, along with Tfh cells, Tph cells, age-associated B cells, and plasma cells in WT mice. CD4+ T cells from IMQ-treated WT mice promoted B-cell differentiation and IgG production in co-culture assays. In IFNγ−/− mice, lupus-like phenotypes were significantly attenuated, and co-cultured B cells showed reduced differentiation and IgG production. Single-cell RNA sequencing revealed that IFNγ plays a critical role in promoting B cell differentiation and autoantibody production. IFNγ derived from activated CD4+ T cells plays a critical role in driving B-cell differentiation and promoting autoantibody production in IMQ-induced lupus.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba City, Ibaraki 305-8575, Japan.
ORCID-Profile: Reona Tanimura, Yuya Kondo, Kotona Furuyama, Saori Abe, Hiroto Tsuboi
Förderung
- GSK Japan Research
- JST
- Science Technology Innovation
Zitieren
APA
Tanimura, R., Kondo, Y., Sato, R., Nishino, R., Nishiyama, T., Tanaka, S., Shimizu, M., Takahashi, H., Furuyama, K., Ohyama, A., Kitada, A., Abe, S., Asashima, H., Miki, H., Tsuboi, H., Matsumoto, I., & Sumida, T. (2026). Pathogenic role of IFNγ from activated CD4+ T cells in lupus model mice induced by topical treatment with toll-like receptor agonist imiquimod. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf079
Vancouver
Tanimura R, Kondo Y, Sato R, Nishino R, Nishiyama T, Tanaka S, et al. Pathogenic role of IFNγ from activated CD4+ T cells in lupus model mice induced by topical treatment with toll-like receptor agonist imiquimod. Clinical and Experimental Immunology. 2026. doi:10.1093/cei/uxaf079
BibTeX
@article{Tanimura2026,
author = {Tanimura, Reona and Kondo, Yuya and Sato, Ryota and Nishino, Ryohei and Nishiyama, Taihei and Tanaka, Shusuke and Shimizu, Masaru and Takahashi, Hiroyuki and Furuyama, Kotona and Ohyama, Ayako and Kitada, Ayako and Abe, Saori and Asashima, Hiromitsu and Miki, Haruka and Tsuboi, Hiroto and Matsumoto, Isao and Sumida, Takayuki},
title = {Pathogenic role of IFNγ from activated CD4+ T cells in lupus model mice induced by topical treatment with toll-like receptor agonist imiquimod},
journal = {Clinical and Experimental Immunology},
year = {2026},
doi = {10.1093/cei/uxaf079}
}
EUVIMED